EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan-Reference-Cited by-同舟云学术

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

Published:2013-07-03 Issue:3 Volume:9 Page:205-214
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Loupakis Fotios,Cremolini Chiara,Fioravanti Anna,Orlandi Paola,Salvatore Lisa,Masi Gianluca,Schirripa Marta,Di Desidero Teresa,Antoniotti Carlotta,Canu Bastianina,Faviana Pinuccia,Sensi Elisa,Lupi Cristiana,Fontanini Gabriella,Basolo Fulvio,Di Paolo Antonello,Danesi Romano,Falcone Alfredo,Bocci Guido

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-013-0284-7.pdf

Reference23 articles.

1. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

2. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

3. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

4. Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

5. De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753–762

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Blood Serum Antagonizes Effects of EGFR/HER2-Targeted Drug Lapatinib on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Биохимия;2024-09-14

2. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance;International Journal of Molecular Sciences;2024-06-28

3. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment;Cancers;2024-03-02

4. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Biochemistry (Moscow);2024-03

5. Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways;Cells;2023-08-08